What We’re Reading: Drug Price Increases; FDA Approvals Rise; Abortion Pill Demand Surge
January 3rd 2024Drugmakers are expected to increase prices on more than 500 drugs early this month; the FDA approved nearly 50% more novel drugs in 2023 than in 2022; the number of Americans who were not pregnant and wanted abortion pills increased by nearly 10 times after the Supreme Court’s 2022 Roe v Wade decision leaked.
Read More
ICYMI: Highlights From ASCO 2023
January 3rd 2024The most-read content from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting including the latest findings in ongoing clinical trials, a panel discussion on Medicare oncology payment models, and the importance of alignment between clinicians and payers on clinical pathways.
Read More
Proposed Guidance for DMD-Related Respiratory Function Evaluation in the UK
January 2nd 2024A multidisciplinary team has proposed respiratory care guidance for pediatric and adult patients living with Duchenne muscular dystrophy (DMD) in the United Kingdom (UK), with these recommendations meant to optimize DMD care day to day and in acute episodes.
Read More
What We’re Reading: Mental Hospitals for Addiction; Insulin Price Cap; e-Cigarette Crackdown
January 2nd 2024Lawmakers contemplate the return of mental health institutions in response to the drug crisis; new measures to rein in insulin prices take effect; FDA intensifies efforts to curb the teen vaping epidemic.
Read More
CareFirst Files Lawsuit Against J&J Over Delay Tactics for Stelara Biosimilars
January 1st 2024While the first ustekinumab biosimilar, Wezlana, was approved in October 2023, a settlement with Johnson & Johnson (J&J) will keep it off the market until 2025, preventing competition, and causing purchasers to pay substantially more for the agent.
Read More
Patients With RA Receiving DMARDs Have Reduced COVID-19 Vaccine Immune Responses, Study Finds
December 31st 2023A cross-sectional study finds that patients with rheumatoid arthritis receiving disease-modifying antirheumatic drugs (DMARDs) exhibit a reduced immune response to the COVID-19 vaccine compared with controls.
Read More
Qualitative Study Explores Caregiver Experiences in SMA Treatment
December 31st 2023This qualitative study conducted interviews with caregivers of patients with spinal muscular atrophy (SMA) to explore their unique experiences and challenges in navigating health systems to access disease-modifying therapies.
Read More
Top 5 Most Popular Reimbursement Content of 2023
December 31st 2023The most popular reimbursement content of 2023 included coverage of the shift from the Oncology Care Model to the Enhancing Oncology Model, reactions to the 2024 Medicare Physician Fee Schedule, and concerns around denial of services in Medicare Advantage plans.
Read More
Vaccines Reduce Declines in Respiratory Parameters Post COVID-19 Among Health Care Workers
December 29th 2023Health care workers who received SARS-CoV-2 vaccinations were found to be protected against declines in respiratory parameters after overcoming COVID-19, highlighting the importance of COVID-19 vaccines for health care workers.
Read More
Descriptions of Physical Limitations, Symptoms of DMD From the Patient, Caregiver Perspective
December 29th 2023A recent study encapsulates how patients and caregivers characterize the impact of Duchenne muscular dystrophy (DMD) on patients’ physical limitations and symptom burden, potentially helping to inform patient-centered strategies for assessing clinical outcomes in DMD research.
Read More
Dr Lalan Wilfong Highlights the Challenges of EOM Compared With OCM
December 28th 2023While the Enhancing Oncology Model is the successor of the Oncology Care Model, it includes some very real challenges for participating practices, explained Lalan Wilfong, MD, senior vice president of payer and care transformation at The US Oncology Network.
Watch